Spotlight Therapeutics Closes $30 Million Series A to Advance ...

Spotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics.

Spotlight Therapeutics, a Calif.-based biotech company focused on in vivo CRISPR (clusters of regularly interspaced short palindromic repeats) ...

Press Releases - Spotlight Therapeutics

July 12, 2022 · Spotlight Therapeutics Appoints Visionary Global Pharma Drug Developer Antoine Yver, M.D., M.Sc. · March 22, 2022 · SPOTLIGHT THERAPEUTICS RAISES ...

Spotlight Therapeutics - IPIRA-Berkeley

Developer of next-generation gene editing therapeutics in a preclinical pipeline. The company creates programmable nucleases that selectively target and edit ...

New Page — Spotlight Therapeutics

Hayward, Calif.-based Spotlight Therapeutics Inc., focus on delivering gene-editing drugs more effectively to sites of disease in the body.

Spotlight Therapeutics nabs $30M to advance nonviral CRISPR ...

Spotlight Therapeutics has closed $30 million in series A financing to advance its nonviral gene editing therapeutics for in vivo editing.

Spotlight Raises $30 Million to Advance Pipeline of Non-Viral ...

Spotlight Therapeutics said it closed a $30 million series A financing round to develop non-viral gene editing therapeutics for direct in vivo ...

Spotlight Therapeutics Closes $30M Series A Led by GV to Advance ...

Spotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics · Carolyn Bertozzi, Ph.D., ...

News | Intellectual Property & Industry Research Alliances

November 30, 2020. Spotlight Therapeutics Closes $30 Million Series A to Advance CRISPR Technology ...

Spotlight Therapeutics: making CRISPR deliver in vivo - Nature

Spotlight Therapeutics was born of a vision to re-imagine CRISPR delivery. The company's three co-founders—Corn; Alex Marson of the University ...

Spotlight Therapeutics Closes its Series A Financing Bringing the ...

Spotlight Therapeutics Closes its Series A Financing Bringing the Total Raised to $30 Million ... Spotlight Therapeutics, Inc., a biotechnology ...

Spotlight Therapeutics company information, funding & investors ...

... Advance A Pipeline Of Cell-Targeted In Vivo Crispr Gene Editing Biologics. Mar 2022 via Business Wire - Funding news · Spotlight Therapeutics Closes $30M Series ...

Spotlight Therapeutics Inc. - [LSUS] Life-Sciences-USA.com

"Press Release: Spotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics". San Francisco, CA. Record ...

Mary J. Janatpour on LinkedIn: Spotlight Therapeutics Closes $30M ...

Mary J. Janatpour's Post · Spotlight Therapeutics Closes $30M Series A Led by GV to Advance Pipeline of Non-viral CRISPR Gene Editing Biologics · More Relevant ...

Spotlight Therapeutics company information, funding & investors

Dec 2020, N/A. $0.0. round ; Mar 2022 *. Emerson Collective · EPIQ Capital Group · Magnetic Ventures · GordonMD Global Investment. $36.5m. Series B ...

Scoop: Google's GV spearheads the Spotlight syndicate — backing ...

And now the Spotlight team is jumping into the industry spotlight with a $30 million launch round to go after lead programs in ...

Spotlight Therapeutics - Recent News & Activity

BioSpace — Spotlight Therapeutics Raises $36.5 Million Series B to Advance a ... Closes $30 Million Series A to Advance CRISPR Technology. Funding Round ...

Spotlight Therapeutics raises $30 million in vivo CRISPR gene editing

Spotlight Therapeutics has raised $30 million in series A financing to develop CRISPR gene-editing therapies for genetic blood diseases and ...

Code Biotherapeutics launches to develop nonviral-based gene ...

Spotlight Therapeutics has closed $30 million in series A financing to advance its nonviral gene editing therapeutics for in vivo editing.

CRISPR Medicine News, 4 December 2020 | Your missing links are ...

California-based biotech Spotlight Therapeutics closes $30 million series A financing round to advance its novel non-viral CRISPR technology.